Physician profile
Patrick Coleman
NPI 1326045428
$11,452.98
in general payments reported to CMS, 2019-2025
31 companies · $208 in 2025
The $208 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,729 · 2020: $3,886 · 2021: $190 · 2022: $132 · 2023: $30.95 · 2024: $278 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $516.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $4,398.54 | 2019-2020 | |
| Abbott Laboratories | $2,125.76 | 2019-2021 | |
| Boston Scientific Corporation | $1,922.15 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $461.43 | 2019-2025 | |
| Edwards Lifesciences Corporation | $400.33 | 2019-2020 | |
| Shockwave Medical, INC | $384.06 | 2020-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Baylis Medical Company INC | $369.57 | 2019 | |
| Abiomed | $323.57 | 2019 | |
| Angiodynamics, INC. | $142.21 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $95.10 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $92.07 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $88.68 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $81.17 | 2019 | |
| Philips North America LLC | $67.49 | 2019-2020 | |
| Astellas Pharma US INC | $65.22 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $46.55 | 2024-2025 | |
| Amarin Pharma, INC. | $46.18 | 2019-2020 | |
| Gilead Sciences, INC. | $43.66 | 2019 | |
| Portola Pharmaceuticals, LLC | $40.78 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $36.68 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $36.63 | 2019 | |
| United Therapeutics Corporation | $36.34 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $26.75 | 2019 | |
| Ge Healthcare | $21.86 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.97 | 2019 | |
| Siemens Medical Solutions USA, INC. | $15.74 | 2019 | |
| Amgen INC. | $14.88 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.89 | 2022 | |
| Aegerion Pharmaceuticals, INC. | $13.44 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.38 | 2019 | |
| Irhythm Technologies, INC. | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.